Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083617 | 0.81 | ENPP2 (0.47) | SRCENPP2DGAT2FFAR1 | |
| SCHEMBL17488978 | 0.80 | PPARD (0.50) | HDAC1NPSR1ENPP2POLBCETP | |
| SCHEMBL915443 | 0.76 | ALDH1A1 (0.53) | HDAC1MAPTPOLBCETP | |
| SCHEMBL10955013 | 0.76 | ALDH1A1 (0.52) | HDAC1SRCMAPTFFAR1POLB | |
| SCHEMBL915800 | 0.76 | TSHR (0.52) | NPSR1POLBCETP | |
| SCHEMBL13715288 | 0.75 | SRC (0.46) | HDAC1SRCNPSR1ENPP2DGAT2 | |
| SCHEMBL914541 | 0.74 | PPARD (0.44) | HDAC1ENPP2MAPTLMNAPOLB | |
| Phosphoric Acid SCHEMBL8605342 | 0.74 | CETP (0.50) | NPSR1POLBCETP | |
| SCHEMBL915441 | 0.74 | PPARD (0.44) | HDAC1ENPP2LMNAPOLBCETP | |
| SCHEMBL915436 | 0.74 | LOXL2 (0.53) | HDAC1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0313002-B1 | Phenyl glycines for use in reducing neurotoxic injury | SEARLE & CO (US) | 1993-12-01 | — | — | EP | claimed |
| US-4918064-A | TREATMENT OF ANOXIA OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-04-17 | — | — | US | claimed |
| EP-0313002-A2 | Phenyl glycines for use in reducing neurotoxic injury | G.D. Searle & Co. (US) | 1989-04-26 | — | — | EP | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| EP-0313002-B1 | Phenyl glycines for use in reducing neurotoxic injury | SEARLE & CO (US) | 1993-12-01 | — | — | EP | disclosed |
| US-4918064-A | TREATMENT OF ANOXIA OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0313002-A2 | Phenyl glycines for use in reducing neurotoxic injury | G.D. Searle & Co. (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | HDAC1 1392/4885SRC 4246/4885NPSR1 137/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | HDAC1 1392/4885SRC 4246/4885NPSR1 137/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | HDAC1 1392/4885SRC 4246/4885NPSR1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.